Pharsight

Austedo generic

Austedo is an anti-dyskinetic drug owned by Teva Branded Pharm. The active ingredient, deutetrabenazine, allows it to be effective in treating conditions like tardive dyskinesia and Huntington's chorea. It was first approved for market use on 03 April, 2017.

When will Austedo generic be available?

The generic release of Austedo is anticipated after 15 September, 2038. This is following the expiry of its last patent, 'Analogs of deutetrabenazine, their preparation and use', set to expire on 15 September, 2038.

Austedo uses

Austedo is primarily used for the treatment of tardive dyskinesia and Huntington's chorea. deutetrabenazine, its active ingredient, has properties that assist in managing and reducing the symptoms of these illnesses.

Austedo patent expiration

Austedo has a total of 23 patents, with none expired as yet. Its last patent, 'Analogs of deutetrabenazine, their preparation and use', will expire on 15 September, 2038, paving way for Austedo generic release. Below are the details of the patent:

Litigations filed on Austedo

Austedo dosage

Want to ask something?